Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AngioDynamics, Inc.
First Human Use Demonstrates Effectiveness of Irreversible Electroporation Treatment
May 9th, 2008
AngioDynamics (NASDAQ:ANGO) reported that the first human clinical use employing irreversible electroporation (IRE) to ablate soft tissue was completely successful based on analysis of biopsies performed on five patients two weeks after their treatment. The IRE treatment was conducted during the first week of April, 2008 as part of a pilot trial focused on determining the success of treating soft tissue with IRE. Biopsies taken from the treated patients' prostates were normal and the patients had no side effects. The trial is expected to continue to develop clinical data on the technology's therapeutic effectiveness. "We are very pleased with the...
Source: Health Business Week (2008-05-09)
|
